Core Viewpoint - 基石药业's stock price increased nearly 7%, currently trading at 6.23 HKD, following the European Commission's approval of a new indication for Shugli monoclonal antibody in treating specific non-small cell lung cancer (NSCLC) patients [1] Group 1: Company Developments - The European Commission has approved Shugli monoclonal antibody for monotherapy in adult patients with unresectable stage III non-small cell lung cancer (NSCLC) who have PD-L1 expression ≥1%, no EGFR sensitive mutations, or ALK/ROS1 genomic alterations, and have not shown disease progression after platinum-based chemoradiotherapy [1] - Dr. Yang Jianxin, CEO and R&D President of 基石药业, stated that this new indication approval marks a significant milestone, providing comprehensive treatment options for a broader patient population in Europe, following the initial approval for first-line treatment of metastatic squamous and non-squamous NSCLC in 2024 [1] - The company aims to enhance the accessibility of Shugli monoclonal antibody globally, reaffirming its long-term commitment to patients [1]
基石药业-B再涨近7% 欧盟委员会批准舒格利单抗用于治疗III期非小细胞肺癌